Jerome D. Jabbour
2021
In 2021, Jerome D. Jabbour earned a total compensation of $3.7M as Chief Executive Officer at Matinas BioPharma Holdings, a 26% increase compared to previous year.
Compensation breakdown
| Bonus | $250,000 |
|---|---|
| Option Awards | $2,898,314 |
| Salary | $545,000 |
| Total | $3,693,314 |
Jabbour received $2.9M in option awards, accounting for 78% of the total pay in 2021.
Jabbour also received $250K in bonus and $545K in salary.
Rankings
In 2021, Jerome D. Jabbour's compensation ranked 3,616th out of 12,405 executives tracked by ExecPay. In other words, Jabbour earned more than 70.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,616 out of 12,405 | 71st |
Division Manufacturing | 1,473 out of 5,494 | 73rd |
Major group Chemicals And Allied Products | 600 out of 2,369 | 75th |
Industry group Drugs | 534 out of 2,090 | 74th |
Industry Pharmaceutical Preparations | 373 out of 1,537 | 76th |
Source: SEC filing on September 22, 2022.
Jabbour's colleagues
We found two more compensation records of executives who worked with Jerome D. Jabbour at Matinas BioPharma Holdings in 2021.
News
Matinas BioPharma Holdings CEO Jerome Jabbour's 2022 pay falls 55% to $1.7M
September 19, 2023
Matinas BioPharma Holdings CEO Jerome Jabbour's 2021 pay jumps 26% to $3.7M
September 22, 2022
Matinas BioPharma Holdings CEO Jerome Jabbour's 2019 pay rises 6% to $1.3M
October 1, 2020
Matinas BioPharma Holdings CEO Jerome Jabbour's 2018 pay slips 1% to $1.3M
September 24, 2019